Dr. Clara Tang (Chief Operations Officer) and Megan Pullein (Senior Scientist) represented Fortuity Pharma at the Aspire Biosciences Rare Metabolic & Liver Disease Partnering Cohort, held at the Royal Society of Medicine in London. This event brought together patient advocacy groups, leading life sciences companies, and innovators to foster collaboration and address the highest unmet needs in rare metabolic and liver diseases.
Thank you to Aspire Biosciences for inviting Fortuity Pharma to participate in this wonderful partnering event. It was great to be able to share our mission and the potential of amlexanox with such a diverse group of patient advocates and life sciences innovators. Connecting with them reinforced the power of collaboration in advancing solutions for rare diseases. These partnerships are vital as we strive to bring hope and impactful therapies to those who need them most.
Engaging with the Rare Disease Community
Collaboration in rare disease research is essential to making progress, and the Aspire Biosciences event provided an invaluable opportunity to connect with key stakeholders. Clara and Megan were thrilled to engage with a wide range of patient groups, whose insights are critical to guiding research and development priorities. These organizations are on the frontlines of driving awareness, supporting families, and advocating for breakthroughs in rare disease care. Their dedication underscores why Fortuity Pharma is committed to advancing therapies for underserved communities.
Sharing Our Mission and Progress
At the event, Clara and Megan shared Fortuity Pharma’s story and the exciting potential of amlexanox, a repurposed drug that holds promise for treating rare diseases caused by nonsense mutations. Our focus on nonsense mutation readthrough and nonsense-mediated decay inhibition resonated with the audience, highlighting the potential to address unmet medical needs in rare diseases with innovative yet pragmatic approaches.
Looking head
Partnerships play a pivotal role in achieving Fortuity Pharma’s mission of developing effective and affordable therapies for rare diseases. We’re grateful to Aspire Biosciences for organizing such an impactful event and for creating a platform to engage with stakeholders across the rare disease ecosystem. The conversations and connections made at the Rare Metabolic & Liver Disease Partnering Cohort are just the beginning, and we’re eager to explore collaborative opportunities to advance our shared goals.
Get in touch! Fill in our Contact Form or email Clara.
